SCHEMBL22623099

SCHEMBL22623099

Cn1c(COc2cccc(C(F)(F)F)c2)nnc1[C@H]1CC[C@H](n2cc([C@H]3CC[C@H](NC(=O)OC(C)(C)C)CC3)cn2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCRL2 O00421 1/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PPARG P37231 3/20 0.37
▸ NR2E3 Q9Y5X4 1/20 0.37
▸ NCOR2 Q9Y618 1/20 0.37
▸ CCR2 P41597 4/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RORC P51449 1/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ PRKDC P78527 1/20 0.35
▸ JAK1 P23458 2/20 0.34
▸ JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30234059 1.00 CCRL2 (0.38) CCRL2RAB9APPARGNR2E3NCOR2
SCHEMBL22227976 0.92 PPARG (0.40) RAB9APPARGNR2E3NCOR2CCR2
SCHEMBL20832656 0.90 RAB9A (0.45) CCRL2RAB9APPARGNR2E3NCOR2
SCHEMBL28430362 0.90 RAB9A (0.45) CCRL2RAB9APPARGNR2E3NCOR2
SCHEMBL22623138 0.86 MAP4K3 (0.36) CCRL2RAB9APPARGNR2E3NCOR2
SCHEMBL28431066 0.86 MAP4K3 (0.36) CCRL2RAB9APPARGNR2E3NCOR2
SCHEMBL20832930 0.85 L3MBTL1 (0.41) RAB9APPARGKMT2AKCNH2L3MBTL1
SCHEMBL28440652 0.84 L3MBTL1 (0.37) RAB9APPARGMEN1KMT2AL3MBTL1
SCHEMBL28434825 0.84 L3MBTL1 (0.37) RAB9APPARGMEN1KMT2AL3MBTL1
SCHEMBL22227776 0.83 HRH3 (0.45) RAB9APPARGCCR2KCNH2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745129-A2 COMPOUND HAVING CYCLIC STRUCTURE Daiichi Sankyo Company, Limited (JP) 2026-05-20 — — EP disclosed
EP-3682881-B1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO CO LTD (JP) 2026-04-01 — — EP disclosed
US-12297187-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-05-13 — — US disclosed
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 — — US disclosed
CN-111094255-B Compounds having cyclic structures 第一三共株式会社 2023-10-03 — — CN disclosed
US-11512067-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-11-29 — — US disclosed
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
CN-111094255-A Compound having cyclic structure 第一三共株式会社 2020-05-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297187-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B CCRL2 691/4885RAB9A 1492/4885PPARG 582/4885
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B CCRL2 691/4885RAB9A 1492/4885PPARG 582/4885
US-11512067-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B CCRL2 691/4885RAB9A 1492/4885PPARG 582/4885
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B CCRL2 691/4885RAB9A 1492/4885PPARG 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback